Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort

Altres autors/es

Institut Català de la Salut

[Osterlund E, Hammarström K, Mathot L, Sjöblom T] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Nunes L] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. [Mezheyeuski A] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2025-08-12T07:13:35Z

2025-08-12T07:13:35Z

2025-05-28



Resum

Primary tumour; Molecular alterations; Metastatic colorectal cancer


Tumor primari; Alteracions moleculars; Càncer colorectal metastàtic


Tumor primario; Alteraciones moleculares; Cáncer colorrectal metastásico


Background: Metastatic colorectal cancer (mCRC) patients in trials are selected. The aim was to study mCRC features population-based. Methods: All 765 mCRC patients in the Uppsala region, Sweden, 2010-2020 were identified and analysed for RAS (n = 356/708) and BRAF-V600E (n = 123/708) mutations (mt) and deficient mismatch repair (dMMR, n = 58/643). Results: Right colon primary tumours were associated with BRAF-V600Emt and dMMR and had worse median overall survival (mOS) than left colon or rectal mCRC. RAS&BRAF wildtype (wt) and proficient MMR were seen in 22%, 45%, and 31% of right colon, left colon, and rectum, respectively. Patients with right colon primaries received best supportive care only more often (34% vs 25% vs 24%) and metastasectomy less often (21% vs 31% vs 33%) than left colon and rectal primaries. In molecularly homogeneous subgroups (RAS&BRAFwt/RASmt/BRAF-V600Emt/dMMR) no difference in mOS were seen between right and left colon primaries, whereas rectal primaries had better mOS (26/15/8/9 vs 24/21/8/8 vs 32/23/6/NA months, respectively). This was also the case in homogenous treatment groups. Primary tumour location turned non-significant in multivariable OS analyses. Conclusions: The high variation of BRAF-V600Emt, RASmt, dMMR, and treatment allocation population-based per primary tumour location explain the poor outcome in right-sided cancers.


This work was funded by grants from the Swedish Cancer Society (22 2054 Pj 01H), Lions Cancerforskningsfond Mellansverige, and an unrestricted start-up grant from Amgen. The funders had no role in the design of the study, nor in the analyses of data or the writing of this report. Open access funding provided by Uppsala University.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Springer Nature

Documents relacionats

BJC Reports;3

https://doi.org/10.1038/s44276-025-00156-z

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)